
## Efisio Puxeddu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2208572/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patient Age–Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	0.8	102
2	Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E832-E840.	1.8	73
3	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
4	Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. Thyroid, 2017, 27, 1490-1497.	2.4	52
5	Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer. Cells, 2019, 8, 547.	1.8	49
6	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3557-3575.	1.8	41
7	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
8	Anti- <i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. Molecular Cancer Therapeutics, 2018, 17, 1187-1195.	1.9	33
9	The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition. Cancers, 2020, 12, 145.	1.7	31
10	Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Molecular and Cellular Endocrinology, 2017, 448, 34-40.	1.6	30
11	Immune Landscape of Thyroid Cancers: New Insights. Frontiers in Endocrinology, 2020, 11, 637826.	1.5	30
12	BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?. Endocrine, 2014, 45, 341-343.	1.1	26
13	Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. Endocrine, 2016, 52, 571-578.	1.1	25
14	Clinical prognosis in BRAF-mutated PTC. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 736-747.	1.3	21
15	THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside. European Journal of Endocrinology, 2020, 183, R41-R55.	1.9	20
16	The iodine nutritional status in the Italian population: data from the Italian National Observatory for Monitoring Iodine Prophylaxis (OSNAMI) (period 2015–2019). American Journal of Clinical Nutrition, 2019, 110, 1265-1266.	2.2	19
17	Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. Journal of Biological Chemistry, 2017, 292, 1785-1797.	1.6	17
18	Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. Cell Death and Disease, 2018, 9, 305.	2.7	16

#	Article	IF	CITATIONS
19	Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid, 2021, 31, 1814-1821.	2.4	15
20	The Stone Guest: How Does pH Affect Binding Properties of PDâ€1/PDâ€11 Inhibitors?. ChemMedChem, 2021, 16, 568-577.	1.6	9
21	What Is New in Thyroid Cancer: The Special Issue of the Journal Cancers. Cancers, 2020, 12, 3036.	1.7	3
22	Editorial: Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Clinical and Genetic Update. Frontiers in Endocrinology, 2022, 13, 891903.	1.5	3